Piribo: New publication announcement, Pricing and Reimbursement in the US

The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer drugs are being approved, a wide number of blockbusters are facing patent expiry, and payers are implementing stringent cost-containment policies in the face of sky-rocketing healthcare costs.#

Highlights
US drug developers need to prioritize P&R as an important factor in drug development, and in particular should place significant emphasis on performing robust pharmacoeconomic analysis to strengthen the case for setting a strong launch price and securing adequate reimbursement.Drug developers should increasingly focus on securing strong P&R justification before green-lighting me-too drugs. If it is not possible to clearly differentiate the drug, then the developer should carefully assess potential ROI, and consider discontinuing development if necessary to optimize resource allocation.To capitalize on changes to the P&R environment, drugs companies must optimize P&R team interaction both internally with other teams such as brand management, and externally with payer decision-makers.

Scope
- Identification of the pressures facing the drugs industry and examination of the implications for P&R
- Overview of the US healthcare market, focusing on identifying key P&R stakeholders
- In-depth analysis of global P&R controls, examining which are important in the US market both currently and in the future
- Best-practice recommendations to help drugs companies capitalize on pricing and reimbursement opportunities to maximize drug ROI
Reasons to Purchase
- Review P&R trends in the US, based on Datamonitor analysis and primary research conducted with key stakeholders in the industry
- Benchmark company performance against best-practice P&R recommendations to develop stronger P&R strategies
- Gain insight into how P&R fits into drug company strategy in the US and identify specific opportunities and threats within this area

Contents
Chapter 1 Executive Summary
Chapter 2 Overview Of The Us Drugs Market: Identifying Why Pricing And Reimbursement Is Important And Where It Fits In
Chapter 3 The Us Healthcare System
Chapter 4 Drug Pricing In The Us
Chapter 5 Drug Reimbursement In The Us
Chapter 6 The Future Of Pricing And Reimbursement In The Us: Best Practice Recommendations
Chapter 7 Appendix : Supporting Data

“Pricing and Reimbursement in the US - Innovation and robust pharmacoeconomic analysis are ke” is available from Piribo. For more information go to: http://www.piribo.com/publications/regulation_policy/pricing_reimbursement_us.html

Piribo Product ID: DAT525

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.